- Home
- TKNO vs AARD Comparison
TKNO vs AARD Comparison
Compare TKNO & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TKNO
- AARD
- Stock Information
- Founded
- TKNO 1996
- AARD 2017
- Country
- TKNO United States
- AARD United States
- Employees
- TKNO N/A
- AARD N/A
- Industry
- TKNO Medicinal Chemicals and Botanical Products
- AARD Biotechnology: Pharmaceutical Preparations
- Sector
- TKNO Health Care
- AARD Health Care
- Exchange
- TKNO Nasdaq
- AARD Nasdaq
- Market Cap
- TKNO 256.9M
- AARD 242.9M
- IPO Year
- TKNO 2021
- AARD 2025
- Fundamental
- Price
- TKNO $4.35
- AARD $8.30
- Analyst Decision
- TKNO
- AARD Strong Buy
- Analyst Count
- TKNO 0
- AARD 5
- Target Price
- TKNO N/A
- AARD $32.60
- AVG Volume (30 Days)
- TKNO 221.4K
- AARD 68.1K
- Earning Date
- TKNO 08-07-2025
- AARD 08-13-2025
- Dividend Yield
- TKNO N/A
- AARD N/A
- EPS Growth
- TKNO N/A
- AARD N/A
- EPS
- TKNO N/A
- AARD N/A
- Revenue
- TKNO $38,923,000.00
- AARD N/A
- Revenue This Year
- TKNO $9.52
- AARD N/A
- Revenue Next Year
- TKNO $15.20
- AARD N/A
- P/E Ratio
- TKNO N/A
- AARD N/A
- Revenue Growth
- TKNO 11.40
- AARD N/A
- 52 Week Low
- TKNO $4.00
- AARD $4.88
- 52 Week High
- TKNO $10.37
- AARD $19.58
- Technical
- Relative Strength Index (RSI)
- TKNO 43.35
- AARD N/A
- Support Level
- TKNO $4.22
- AARD N/A
- Resistance Level
- TKNO $4.94
- AARD N/A
- Average True Range (ATR)
- TKNO 0.29
- AARD 0.00
- MACD
- TKNO -0.00
- AARD 0.00
- Stochastic Oscillator
- TKNO 16.75
- AARD 0.00
About TKNO Alpha Teknova Inc.
Alpha Teknova Inc provides critical reagents that enable the discovery, development, and production of biopharmaceutical products such as drug therapies, novel vaccines, and molecular diagnostics. Its offer three product types: pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It derives key revenue from United States.
About AARD Aardvark Therapeutics Inc. Common Stock
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.